Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.
about
Focal therapy in prostate cancer: the current situationDeveloping and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study).Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer.Long-term functional outcomes after treatment for localized prostate cancer.Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer.Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysisClinical management and burden of prostate cancer: a Markov Monte Carlo model.Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?Mapping of lymphatic drainage from the prostate using filtered 99mTc-sulfur nanocolloid and SPECT/CT.Early Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost.Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomesLate gastrointestinal toxicities following radiation therapy for prostate cancer.Management of high-risk localized prostate cancer.Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.A surveillance study of intensity-modulated radiation therapy for postoperative cervical cancer in JapanIntravesical Glycosaminoglycan Replacement with Chondroitin Sulphate (Gepan(®) instill) in Patients with Chronic Radiotherapy- or Chemotherapy-Associated CystitisRadioresistance of prostate cancer cells with low proteasome activity.Extracting the Benefit of Nexrutine® for Cancer Prevention.Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.Analysis of late toxicity associated with external beam radiation therapy for prostate cancer with uniform setting of classical 4-field 70 Gy in 35 fractions: a survey study by the Osaka Urological Tumor Radiotherapy Study Group.Multi-Parametric MRI-Directed Focal Salvage Permanent Interstitial Brachytherapy for Locally Recurrent Adenocarcinoma of the Prostate: A Novel Approach.Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinomaPatient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.Antitumor effects of (32)P-chromic-poly (L-lactide) brachytherapy in nude mice with human prostate cancerSevere genitourinary toxicity following radiation therapy for prostate cancer--how long does it last?CT Simulation to Evaluate of Pelvic Lymph Node Coverage in Conventional Radiotherapy Fields Based on Bone and Vessels Landmarks in Prostate Cancer Patients.Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report.Outcomes of high-dose intensity-modulated radiotherapy alone with 1 cm planning target volume posterior margin for localized prostate cancer.Current and emerging treatments in the management of castration-resistant prostate cancer.Re-irradiation for salvage of prostate cancer failures after primary radiotherapy.Clinical controversies: proton therapy for prostate cancer.African American prostate cancer survivorship: Exploring the role of social support in quality of life after radical prostatectomy.Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.Post-Prostatectomy Image-Guided Radiotherapy: The Invisible Target Concept.Stamp test delivers message on erectile dysfunction after high-dose intensity-modulated radiotherapy for prostate cancer.Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer.
P2860
Q28242346-F7C5093B-0AC0-4FCC-8FF3-6D1FD02F0071Q30151845-4C3D2466-BDBE-4D93-9544-7864EE4EC662Q30376901-591E947D-CED0-486A-B73D-84B41EA47ADFQ30542816-600991D5-5726-4D4F-B3FB-40CC373580DFQ33651525-AF8BB83B-9038-44F8-8DA6-107EF381A213Q33679365-8B4B4D45-1FA0-44E5-8E36-B3BF6A0866D7Q34413524-F6DEE6A7-F9C2-4C6B-8CB7-9238B08DACBFQ34500966-7B4E3021-4458-47D9-86A0-CA1DF4201685Q34634410-1E856812-E29A-46F7-8115-436A8ED0A2E5Q34810730-E304FCDA-1C98-4C30-89A1-8DC7895F1865Q35085833-B727C55C-9A4A-4B0B-877F-B9FD825D4135Q35111988-4EFBBAAC-2F9B-4763-83D6-EFD8AD6B5F14Q35212795-EBC7891F-6733-4A89-96C2-868B35D0AA90Q35256076-69366220-C245-4A4D-8FAE-F783D6C33AB5Q35503645-48DFD64F-343E-4DD2-853F-3F78C75109B2Q35515150-68BC712C-AE6F-43AD-BAD8-DDBA3F4BEE3AQ35835126-A3303610-E4B0-4B36-9EA2-E5A6B8A59B50Q35901614-5795F1CF-1F4B-4232-BD77-BEE6D442EC80Q36094487-D57879E7-FA1D-4864-A834-E9D788B5CD72Q36236997-58C56EFC-D9CE-4EF3-8123-95ECFC519F50Q36384072-56510074-4BBC-4835-8C84-9E917A080446Q36500061-53052287-A8A9-4F2B-B760-C305606B7889Q36609888-11F7C4E8-575F-48DD-AADB-CB71E690D173Q36921562-8DB38E7F-641B-486A-B5ED-8923E547E39DQ37139334-6EB5FCF0-CC42-4A6B-BBDB-702F2CBAB1B7Q37195789-7765F9E1-BA6B-4162-85D2-0EC61FE24D62Q37211798-02138607-3C24-483D-B4C3-81BD19E5494CQ37284915-4B368776-D036-44A5-8361-B7988883CD2FQ37289333-0DEEBEDC-2D2F-4DB5-9F57-6D315D0887E5Q37549491-9E090EA9-D112-475A-938F-F1D3192C7466Q37717598-201D778E-6DF4-41A3-997A-E8D9E76B8C2CQ38030595-55902371-0B58-4E99-B519-C3E88A5EE426Q38051008-4F60AC96-8191-48DA-9F98-BF2C5C2B5E04Q38087711-4A07F3E7-0355-4BB2-86D3-119592A387C5Q38557906-EC546212-49BA-43BE-87EF-559E8419D3D9Q38640272-E8FEE548-51C9-4152-96B5-4B91157C0362Q39088175-84EF3BE6-5711-411B-A1AD-86A54A14BDE2Q39197792-5CF98D30-B13C-4115-B5C6-9390D5A675E6Q39593619-511CC380-6BE4-4A0C-8E3F-23CE4A3FA69CQ39701289-A05EDBE1-8EF0-4294-95C6-76AECFAD31CC
P2860
Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Ten-year outcomes of high-dose ...... for localized prostate cancer.
@en
Ten-year outcomes of high-dose ...... for localized prostate cancer.
@nl
type
label
Ten-year outcomes of high-dose ...... for localized prostate cancer.
@en
Ten-year outcomes of high-dose ...... for localized prostate cancer.
@nl
prefLabel
Ten-year outcomes of high-dose ...... for localized prostate cancer.
@en
Ten-year outcomes of high-dose ...... for localized prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Ten-year outcomes of high-dose ...... for localized prostate cancer.
@en
P2093
Marisa Kollmeier
Yoshiya Yamada
Zhigang Zhang
Zumre A Alicikus
P2860
P304
P356
10.1002/CNCR.25467
P407
P577
2010-11-08T00:00:00Z